We occasionally blog about motion in limine rulings, but not nearly as often as we read this type of decision. Let’s face it, as blogging material (as opposed to their impact on a particular case) decisions on motions in limine can be pretty boring. You can talk about this; you can’t talk about that. In modern prescription medical product mass tort litigation, the plaintiff usually has about fifteen stock motions, whereas the defendant probably has between 35 and 50. Motion in limine decisions are usually a matter of checking off this or that from a long list. We read them – well at least Bexis does, because he has to update the evidentiary chapter for his book – but usually there’s not enough there there for a blogpost
Hill, 2013 WL 1953753, at *5. A Parisian opinion lacking proper foundation? No surprise there. And without the opinion – well, plainly, ghostwriting is of no inherent relevance to anything.